Shares of Bristol-Myers Squibb (BMY) reached a 14-year high Monday after the pharma giant said a day earlier that a phase three trial of its drug Opdivo resulted in “superior overall survival” in the lung-cancer patients who took it. The results mark the first time a drug of Opdivo’s kind suggested a survival advantage in lung-cancer patients, the company said Sunday in a release. Shares rallied 4.4% on the stock market today to their highest
While the approval of AbbVie’s (ABBV) hepatitis C regimen Viekira Pak hogged most of the headlines, over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here’s a short list of some of the most significant: Bristol-Myers (BMY) won approval for Opdivo for melanoma on Monday, which was something of a surprise since the FDA’s deadline was in March. Opdivo is a PD-1 inhibitor, a hot new class
Big pharma Bristol-Myers Squibb (BMY) reported good midstage trial results for its drug candidate Opdivo in advanced squamous-cell lung cancer, sending its stock up nearly 8% to a 13-year high in early trading in the stock market today. The company released the abstract summarizing its Friday presentation at the Chicago Multidisciplinary Symposium on Thoracic Oncology, describing results of the Checkmate-063 trial. The patients in the trial were